Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (NCT04656652)

🧪 Interventions in This Study

• DS-1062a (DRUG)
• Docetaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (209 Sites)

Showing the first 25 of 209 sites.

• Ironwood Cancer and Research Center — Chandler, Arizona
• St. Joseph Heritage Healthcare — Anaheim, California
• The Oncology Institute of Hope and Innovation — Glendale, California
• University of California San Diego — La Jolla, California
• UCLA — Los Angeles, California
• PIH Health — Whittier, California
• Memorial Healthcare System- Memorial Cancer Institute — Hollywood, Florida
• Orlando Health — Orlando, Florida
• Florida Cancer Specialists — Tallahassee, Florida
• Northwestern University — Chicago, Illinois
• University of Chicago — Chicago, Illinois
• Ft. Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
• Baptist Health Louisville — Louisville, Kentucky
• Baton Rouge General — Baton Rouge, Louisiana
• American Oncology Partners of Maryland — Bethesda, Maryland
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Karmanos Cancer Institute — Detroit, Michigan
• OptumCare Cancer Care — Las Vegas, Nevada
• Meridian Hematology and Oncology — Manahawkin, New Jersey
• Astera Cancer Care — Somerset, New Jersey
• Montefiore Medical Center — The Bronx, New York
• Messino Cancer Centers — Asheville, North Carolina
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• Roger Williams Medical Center — Providence, Rhode Island
• Avera Cancer Institute — Sioux Falls, South Dakota

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-small Cell Lung Cancer

• Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
• Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts

Explore by condition: All Non-small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.